Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

被引：0
|
作者：
Llovet, Josep M.
Singal, Amit G.
Villanueva, Augusto
Finn, Richard S.
Kudo, Masatoshi
Galle, Peter R.
Wang, Chunxiao
Widau, Ryan C.
Gugel, Elena Gonzalez
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, Div Liver Dis, Tisch Canc Inst, New York, NY 10029 USA
[2] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA
[3] Icahn Sch Med Mt Sina, Dept Med, Div Liver Dis, Mt Sinai, NY USA
[4] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[5] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[6] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany
[7] Eli Lilly & Co, Indianapolis, IN 46285 USA
[8] Eli Lilly, Indianapolis, IN USA
[9] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4146
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study
    Shao, Guoliang
    Bai, Yuxian
    Yuan, Xianglin
    Chen, Xiaomin
    Gu, Shanzhi
    Gu, Kangsheng
    Hu, Chunhong
    Liang, Houjie
    Guo, Yabing
    Wang, Jufeng
    Yen, Chia-Jui
    Lee, Victor Ho-Fun
    Wang, Chunxiao
    Widau, Ryan C.
    Zhang, Wanli
    Liu, Junjun
    Zhang, Qiang
    Qin, Shukui
    ECLINICALMEDICINE, 2022, 54
  • [42] Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
    Teufel, Michael
    Kochert, Karl
    Meinhardt, Gerold
    Bruix, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Long-term Kinetics of Alpha-fetoprotein in Chronic Hepatitis C Patients Treated with Direct-acting Antivirals and Possible Predictive Role of AFP Response to Treatment on Development of Hepatocellular Carcinoma
    Ulasoglu, Celal
    Senates, Banu Erkalma
    Yapali, Suna
    Dumanoglu, Betul
    Enc, Feruze
    Colak, Yasar
    Senates, Ebubekir
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2021, 27 (02): : 49 - 52
  • [44] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib
    Gerken, G.
    Zhu, A.
    Kang, Y-K
    Yen, C-J
    Finn, R.
    Galle, P.
    Llovet, J.
    Assenat, E.
    Brandi, G.
    Lim, H. Y.
    Pracht, M.
    Rau, K-M
    Merle, P.
    Motomura, K.
    Ohno, I
    Daniele, B.
    Shin, D. B.
    Abada, P. B.
    Hsu, Y.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 253 - 254
  • [45] PROGNOSTIC LIVER SECRETOME SIGNATURE AND ALPHA-FETOPROTEIN (PLSEC-AFP) PREDICTS LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN PATIENTS WITH CIRRHOSIS: A NATIONWIDE PHASE 3 BIOMARKER STUDY IN THE US
    Fujiwara, Naoto
    Marsh, Tracey L.
    Marquez, Cesia A.
    Raman, Indu
    Li, Quan-Zhen
    Parikh, Neehar D.
    Roberts, Lewis R.
    Schwartz, Myron
    Nguyen, Mindie H.
    Befeler, Alex
    Page-Lester, Stephanie
    Srivastava, Sudhir
    Rinaudo, Jo Ann
    Feng, Ziding
    Marrero, Jorge A.
    Reddy, K. Rajender
    Singal, Amit G.
    Hoshida, Yujin
    GASTROENTEROLOGY, 2022, 162 (07) : S1140 - S1140
  • [46] Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma:: results from two French clinical trials
    Bonnetain, Franck
    Paoletti, Xavier
    Collette, Sandra
    Doffoel, Michel
    Bouche, Olivia
    Raoul, Jean Luc
    Rougier, Philippe
    Masskouri, Fadil
    Barbare, Jean Claude
    Bedenne, Laurent
    QUALITY OF LIFE RESEARCH, 2008, 17 (06) : 831 - 843
  • [47] Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
    Franck Bonnetain
    Xavier Paoletti
    Sandra Collette
    Michel Doffoel
    Olivia Bouché
    Jean Luc Raoul
    Philippe Rougier
    Fadil Masskouri
    Jean Claude Barbare
    Laurent Bedenne
    Quality of Life Research, 2008, 17 : 831 - 843
  • [48] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Finn, Richard S.
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Lim, Ho Yeong
    Pracht, Marc
    Rau, Kun-Ming
    Merle, Philippe
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Shin, Dongbok
    Gerken, Guido
    Abada, Paolo
    Hsu, Yanzhi
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Serum Alpha-Fetoprotein (AFP) and Prothrombin Induced by Vitamin K Absence of Antagonist-II (PIVKA-II) as Predictors for Tumor Response in Locally Advanced Hepatocellular Carcinoma Patients Treated with Radiotherapy
    Kim, S.
    Koom, W.
    Seong, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S286 - S287
  • [50] Analysis of prognostic factors in chemo-naive patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials.
    O'Brien, M.
    Bonomi, P.
    Langer, C.
    O'Byrne, K.
    Bandstra, B.
    Ross, H.
    Sandler, A.
    Socinski, M.
    Paz-Ares, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
12345